6-K filed Aug 6, 2026 at 11:54 ET
Ascendis Pharma provided a comprehensive update on its achondroplasia programs, including Week 78 data from the COACH combination therapy trial showing durable growth at or above the 97th percentile, and Week 104 data from the ApproaCH monotherapy trial confirming durable height improvements and benefits beyond height. The filing also noted completed enrollment for the pivotal reACHin infant trial and an anticipated EU regulatory decision for TransCon CNP in Q4 2026, alongside a U.S. launch update for YUVIWEL with over 170 patient enrollments. This is a positive clinical and regulatory update that reinforces the pipeline's potential, though no new financial data or revenue figures were provided.